Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
Standard
Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest. / Schaeffer, Lisa; Ben-Anaya, Nesrine; Sorbe, Christina; Rustenbach, Stephan Jeff; Mrowietz, Ulrich; Augustin, Matthias.
In: J DERMATOL TREAT, Vol. 35, No. 1, 1, 12.2024, p. 2340107.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
AU - Schaeffer, Lisa
AU - Ben-Anaya, Nesrine
AU - Sorbe, Christina
AU - Rustenbach, Stephan Jeff
AU - Mrowietz, Ulrich
AU - Augustin, Matthias
PY - 2024/12
Y1 - 2024/12
N2 - Brodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profiles, treatment outcomes, and drug survival of first-time use of brodalumab for 12 months in adult patients with moderate-to-severe plaque-type psoriasis (with and without PsA) (data cutoff: June 30, 2021). Clinician and patient-reported outcomes of the total cohort (n = 227; PsA, n = 38) indicated a rapid response to brodalumab treatment within the first 3 months, which was maintained up to 12 months. The overall one-year drug survival rate was 76.2%, the mean time to discontinuation was 8.3 months. Reasons for discontinuation were mainly loss/lack of effectiveness, followed by adverse events, contraindication and skin clearance. In sum, brodalumab demonstrated rapid and sustained effectiveness and was well-tolerated over 12 months in German patients with moderate-to-severe psoriasis and PsA in a real-world setting.
AB - Brodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profiles, treatment outcomes, and drug survival of first-time use of brodalumab for 12 months in adult patients with moderate-to-severe plaque-type psoriasis (with and without PsA) (data cutoff: June 30, 2021). Clinician and patient-reported outcomes of the total cohort (n = 227; PsA, n = 38) indicated a rapid response to brodalumab treatment within the first 3 months, which was maintained up to 12 months. The overall one-year drug survival rate was 76.2%, the mean time to discontinuation was 8.3 months. Reasons for discontinuation were mainly loss/lack of effectiveness, followed by adverse events, contraindication and skin clearance. In sum, brodalumab demonstrated rapid and sustained effectiveness and was well-tolerated over 12 months in German patients with moderate-to-severe psoriasis and PsA in a real-world setting.
KW - Adult
KW - Humans
KW - Arthritis, Psoriatic/drug therapy
KW - Antibodies, Monoclonal, Humanized/therapeutic use
KW - Psoriasis/chemically induced
KW - Antibodies, Monoclonal/therapeutic use
KW - Treatment Outcome
KW - Severity of Illness Index
U2 - 10.1080/09546634.2024.2340107
DO - 10.1080/09546634.2024.2340107
M3 - SCORING: Journal article
C2 - 38636941
VL - 35
SP - 2340107
JO - J DERMATOL TREAT
JF - J DERMATOL TREAT
SN - 0954-6634
IS - 1
M1 - 1
ER -